Cabenuva Kit
NDC Package 49702-240-15
Package Information
Cabenuva (cabotegravir and rilpivirine) kits is cABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine [see Clinical Studies (14.1)]. This formulation utilizes a kit delivery system. Marketed by Viiv Healthcare Company, this product is identified by NDC 49702-240 and is authorized under FDA application NDA212888.
Identification & Billing
- RxCUI: 2475415 - {1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack
- RxCUI: 2475415 - cabotegravir 600 MG / rilpivirine 900 MG Extended Release Kit
- RxCUI: 2475416 - {1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 600 MG / 900 MG]
- RxCUI: 2475416 - CABENUVA 600 MG / 900 MG Extended Release Kit
- RxCUI: 2475417 - {1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 49702 - Viiv Healthcare Company
- 49702-240 - Cabenuva
- 49702-240-15 - 1 KIT in 1 CARTON * 3 mL in 1 VIAL (49702-238-01) * 3 mL in 1 VIAL (49702-243-02)
- 49702-240 - Cabenuva
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 49702-240-15 identifies a specific commercial package of 1 kit in 1 carton * 3 ml in 1 vial (49702-238-01) * 3 ml in 1 vial (49702-243-02) of Cabenuva, a human prescription drug labeled by Viiv Healthcare Company. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viiv Healthcare Company on January 21, 2021. The current certification is valid through December 31, 2026.
How is this Viiv Healthcare Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 49702024015. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
